Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2013

View Archived Issues

Development and characterization of a second-generation inhibitor of tumorigenesis

Rhythm receives Michael J. Fox Foundation grant to advance RM-131

AAV8 gene therapy corrects experimental primary hyperoxaluria type 1

Camurus receives option-exercise milestone for CAM-2029

AstraZeneca and Merck & Co. enter license agreement for Wee1 kinase inhibitor

New agents for pruritus patented by Leo Pharma

Nektar Therapeutics presents novel polymer conjugated antimicrobial peptide NKTR-223

Novel tricyclic S1P1 modulators disclosed by Bristol-Myers Squibb

Bacteriophage lysin from ContraFect shows activity against S. aureus

Novel CKI inhibitors with circadian rhythm effects identified by Pfizer

Kiadis Pharma completes 5-year follow-up of phase I/II ATIR study

Japanese group presents new EGFR inhibitors for cancer

MEI Pharma acquires PWT-143 from Pathway Therapeutics

Allergan discloses novel S1P1 receptor ligands for pain and other disorders

Omeros reports additional data from OMS-824 program

Association between pulmonary tuberculosis and TLR1 and IL17A genes

NeoStem receives NIH grant to study treatment for skin wounds in scleroderma

Ceftazidime/avibactam combination receives FDA QIDP designation

New Nampt inhibitors synthesized at Genentech and FORMA Therapeutics

Oligomerix receives NIH grant for Alzheimer's disease therapeutic discovery

Piramal Enterprises discloses novel GPR40 agonists

Relypsa reports data on part A of its phase III patiromer trial

Soliris approved in Japan for atypical hemolytic uremic syndrome

Procysbi approved in E.U. for nephropathic cystinosis

Versartis obtains European orphan drug status for VRS-317

Nesp approved in Japan for pediatric patients

Scynexis grants R-Pharm rights to SCY-078 in Russia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...